What the Agenus-MiNK Therapeutics combination reveals about the next phase of GI cancer immunotherapy
Agenus brings botensilimab, balstilimab, and agenT-797 to AACR 2026. Read why this refractory GEC update matters and what risks remain.
Can Insight Health turn voice-first clinical agents into a durable healthcare infrastructure layer?
Insight Health raised $11m to expand healthcare admin AI. Read what this funding means for scaling, adoption, and clinical workflow change.
Alpha Cognition expands ALPHA-1062 into traumatic brain injury, but approval is still a distant goal
Alpha Cognition won a U.S. patent for ALPHA-1062 in TBI. Read why the IP matters, what it changes, and where the biggest risks still remain.
What Alto Neuroscience’s ALTO-101 setback reveals about the difficulty of treating cognitive impairment in schizophrenia
Alto Neuroscience’s ALTO-101 missed in Phase 2. Read what the setback means for schizophrenia cognition, partnering prospects, and ALTO-207 next.
Premier Radiology Services deepens outpatient teleradiology push with Global Imaging Solutions
Premier Radiology Services has acquired Global Imaging Solutions. Read what the teleradiology deal changes for outpatient imaging and market competition.
Why Gilead’s Arcellx tender extension matters more for cell therapy execution than for deal timing
Gilead extended its Arcellx tender offer. Read why the move matters for anito-cel, oncology M&A, and cell therapy execution risk.
Plixorafenib breakthrough status raises the stakes for FORE Biotherapeutics in BRAF-mutant high-grade glioma
FORE Biotherapeutics won FDA breakthrough status for plixorafenib in high-grade glioma. Read what this changes and what risks still remain.
What Certis Oncology Intelligence reveals about the next phase of AI in cancer R&D
Certis Oncology has launched a new AI platform for translational oncology. Read what it could change for cancer drug development.
Can Merck’s enlicitide decanoate become the oral PCSK9 breakthrough cholesterol care has been waiting for?
Merck’s enlicitide decanoate beat oral rivals in Phase 3. Read what this could change for cholesterol care, PCSK9 adoption, and market strategy.
How Alnylam Pharmaceuticals is using new ACC.26 data to deepen the case for vutrisiran and zilebesiran
See why Alnylam Pharmaceuticals’ new ACC.26 data on vutrisiran and zilebesiran could reshape cardiovascular strategy and market expectations.